e-therapeutics plc (LON:ETX – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 9.85 ($0.13) and traded as low as GBX 9 ($0.12). e-therapeutics shares last traded at GBX 9 ($0.12), with a volume of 2,518,125 shares traded.
e-therapeutics Stock Performance
The company has a market cap of £52.59 million, a price-to-earnings ratio of -450.00 and a beta of 0.46. The company has a debt-to-equity ratio of 0.33, a current ratio of 22.20 and a quick ratio of 20.13. The firm has a fifty day simple moving average of GBX 9 and a 200 day simple moving average of GBX 9.85.
e-therapeutics Company Profile
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
See Also
- Five stocks we like better than e-therapeutics
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
